MedPath

Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States

Completed
Conditions
Cervical Dystonia
Blepharospasm
Interventions
Biological: Xeomin®
Registration Number
NCT01287247
Lead Sponsor
Merz North America, Inc.
Brief Summary

This is a prospective, observational trial evaluating the "real world" use of Xeomin®(incobotulinumtoxinA). Physicians may enroll patients who are eligible to be treated with a botulinum toxin for cervical dystonia or blepharospasm based upon their clinical experience. The physician must have chosen to treat the patient with Xeomin® (incobotulinumtoxinA) prior to and independent of enrollment in this study. Physicians may choose to treat their subjects with up to 2 treatment cycles (approximately 6 months/subject) of Xeomin® (incobotulinumtoxinA) at a dose determined by the physician based upon his/her clinical experience with botulinum toxin. According and dependent on clinical practice, the investigators expect that subjects will be seen by the investigator for an average of 3 visits (two treatment cycles).

Detailed Description

The primary objective of this trial is to collect, evaluate, and report observational data about the clinical use of Xeomin® in a "real world" setting to determine which muscles are injected, the dose used, and how doctors administer the injection.

The secondary objectives of this trial are: To collect and evaluate information about the efficacy of Xeomin®. To collect and evaluate information about the effect of Xeomin® on work productivity and quality of life. To monitor for any serious side effects and non-serious related side effects of Xeomin®

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
688
Inclusion Criteria
  • Subjects 18 years of age or older.
  • The physician must have chosen to treat the patient with Xeomin® (incobotulinumtoxinA) prior to and independent of enrollment in this study.
  • Subjects who are eligible to be treated with a botulinum toxin for cervical dystonia or blepharospasm based upon the physicians' clinical experience. There are no restrictive subject entry criteria.
  • Subjects who are able to read, speak and understand English.
Exclusion Criteria
  • Subjects who are enrolled in any clinical trial (currently or within the past 3 months) in which treatments are imposed by a protocol are not eligible for this trial.
  • Any subject for whom botulinum toxin treatment would be contraindicated; see Xeomin® Prescribing Information for further details.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Cervical DystoniaXeomin®The target populations for which the sample size calculations are based are adult subjects aged ≥ 18 years with clinical diagnoses of cervical dystonia.
BlepharospasmXeomin®The target populations for which the sample size calculations are based are adult subjects aged ≥ 18 years with clinical diagnoses of blepharospasm.
Primary Outcome Measures
NameTimeMethod
Determination of injection patterns and techniquesTwo treatment cycles (approximately 6 months/subject)

To collect, evaluate and report observational data about the clinical use of Xeomin® in a "real world" setting to determine injection patterns and use of guidance techniques.

Secondary Outcome Measures
NameTimeMethod
To collect and evaluate efficacy of Xeomin®(incobotulinumtoxinA) including onset and offset of effect as well as improvement of disease specific and global illness severityTwo treatment cycles (approximately 6 months/subject)

Trial Locations

Locations (69)

Site #001979

🇺🇸

Virginia Beach, Virginia, United States

Merz Investigative Site #001986

🇺🇸

Los Angeles, California, United States

Site # 001972

🇺🇸

Chicago, Illinois, United States

Site # 001813

🇺🇸

Houston, Texas, United States

Site #001802

🇺🇸

Houston, Texas, United States

Site # 001957

🇺🇸

Minneapolis, Minnesota, United States

Site # 001951

🇺🇸

Durham, North Carolina, United States

Site #001052

🇺🇸

Cullman, Alabama, United States

Site #001046

🇺🇸

Encinitas, California, United States

Site # 001974

🇺🇸

Tucson, Arizona, United States

Site # 001852

🇺🇸

La Jolla, California, United States

Site # 001924

🇺🇸

Los Gatos, California, United States

Site # 001005

🇺🇸

Newport Beach, California, United States

Site # 001901

🇺🇸

Washington, District of Columbia, United States

Site # 001803

🇺🇸

Boca Raton, Florida, United States

Site # 001805

🇺🇸

North Palm Beach, Florida, United States

Site # 001823

🇺🇸

Saint Petersburg, Florida, United States

Site # 001955

🇺🇸

Sarasota, Florida, United States

Site #001057

🇺🇸

Glenview, Illinois, United States

Site # 001820

🇺🇸

Winfield, Illinois, United States

Site # 001833

🇺🇸

Overland Park, Kansas, United States

Site # 001047

🇺🇸

Baton Rouge, Louisiana, United States

Site # 001849

🇺🇸

Baltimore, Maryland, United States

Site # 001816

🇺🇸

Roseville, Michigan, United States

Site # 001053

🇺🇸

Boston, Massachusetts, United States

Site # 001848

🇺🇸

Warren, Michigan, United States

Site # 001834

🇺🇸

Eagan, Minnesota, United States

Site # 001010

🇺🇸

Las Vegas, Nevada, United States

Site # 001838

🇺🇸

St. Louis, Missouri, United States

Site # 001954

🇺🇸

Reno, Nevada, United States

Site #001961

🇺🇸

Toms River, New Jersey, United States

Site # 001860

🇺🇸

Kingston, New York, United States

Site # 001910

🇺🇸

New York, New York, United States

Site # 001041

🇺🇸

New York, New York, United States

Site # 001921

🇺🇸

New York, New York, United States

Site # 001034

🇺🇸

North Syracuse, New York, United States

Site # 001812

🇺🇸

Cleveland, Ohio, United States

Merz Investigative Site # 001840

🇺🇸

Bellevue, Ohio, United States

Site # 001826

🇺🇸

Columbus, Ohio, United States

Site # 001916

🇺🇸

Bend, Oregon, United States

Site # 001839

🇺🇸

Medford, Oregon, United States

Site # 001959

🇺🇸

Philadelphia, Pennsylvania, United States

Site # 001893

🇺🇸

Spartanburg, South Carolina, United States

Site #001000

🇺🇸

Collegeville, Pennsylvania, United States

Site # 001922

🇺🇸

Chattanooga, Tennessee, United States

Site # 001889

🇺🇸

Columbia, Tennessee, United States

Site # 001836

🇺🇸

Nashville, Tennessee, United States

Site # 001831

🇺🇸

Memphis, Tennessee, United States

Merz Investigative Site # 001055

🇺🇸

Bedford, Texas, United States

Site # 001055

🇺🇸

Bedford, Texas, United States

Site # 001817

🇺🇸

Dallas, Texas, United States

Site # 001037

🇺🇸

Bedford, Texas, United States

Site # 001809

🇺🇸

Dallas, Texas, United States

Site # 001022

🇺🇸

Houston, Texas, United States

Site # 001960

🇺🇸

Tyler, Texas, United States

Site # 001962

🇺🇸

Alexandria, Virginia, United States

Site # 001980

🇺🇸

Fishersville, Virginia, United States

Site # 001881

🇺🇸

Kirkland, Washington, United States

Site # 001800

🇺🇸

Spokane, Washington, United States

Site # 001815

🇺🇸

Tulsa, Oklahoma, United States

Site # 001028

🇺🇸

Bloomington, Minnesota, United States

Site # 001013

🇺🇸

Syracuse, New York, United States

Site # 001822

🇺🇸

Fountain Valley, California, United States

Site #001978

🇺🇸

Lake Bluff, Illinois, United States

Site #001032

🇺🇸

Wynnewood, Pennsylvania, United States

Site # 001995

🇺🇸

Munster, Indiana, United States

Site # 001802

🇺🇸

Des Peres, Missouri, United States

Site # 001973

🇺🇸

Sacramento, California, United States

Site # 001977

🇺🇸

New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath